DIMENSIONAL FUND ADVISORS LP
Position in CRNX — Crinetics Pharmaceuticals, Inc.
CIK 354204
AUSTIN, TX
Position in CRNX
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$30,954,008
+$5,399,131 QoQ
Shares Held
852,258
+55.2% QoQ
Ownership
0.808%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
21 quarters on record
Voting authority
Sole 89.41764113683884.ToString("F0")%
Shared 8.15985300225988.ToString("F0")%
None 2.4225058609012766.ToString("F0")%
Common Shares in CRNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026DIMENSIONAL FUND ADVISORS LP holds $5,003,215,874 across 223 Biotechnology names. CRNX ranks #38 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
989,342 | $441,780,774 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
513,060 | $396,410,676 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,895,215 | $358,290,394 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
3,802,930 | $214,827,514 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
7,475,866 | $207,081,486 | |
| 6 | INCY |
Incyte Corp
|
1,975,544 | $185,938,199 | |
| 7 | EXEL |
Exelixis, Inc.
|
4,299,597 | $184,409,714 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
2,079,827 | $134,419,216 |
All Filings in CRNX
Export CSV
21 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,954,008 | 852,258 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $25,554,877 | 548,977 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $15,735,451 | 377,802 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $5,040,390 | 175,257 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $661,509 | 19,723 | Shares | Sole | 2025-05-13 | |
| 2024-09-30 | $20,041,214 | 392,196 | Shares | Sole | 2024-11-07 | |
| 2024-06-30 | $24,489,334 | 546,759 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $29,995,939 | 640,802 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $23,479,987 | 659,921 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $22,150,825 | 744,816 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $9,354,341 | 519,109 | Shares | Sole | 2023-08-09 | |
| 2023-03-31 | $7,220,653 | 449,605 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $9,311,915 | 508,848 | Shares | Sole | 2023-02-09 | |
| 2022-09-30 | $10,528,413 | 536,070 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $10,329,691 | 553,871 | Shares | Sole | 2022-08-12 | |
| 2022-03-31 | $10,741,386 | 489,357 | Shares | Defined | 2022-05-13 | |
| 2021-12-31 | $9,814,064 | 345,444 | Shares | Defined | 2022-02-09 | |
| 2021-09-30 | $6,553,791 | 311,344 | Shares | Defined | 2021-11-12 | |
| 2021-06-30 | $3,492,773 | 185,293 | Shares | Defined | 2021-08-12 | |
| 2021-03-31 | $1,004,201 | 65,720 | Shares | Defined | 2021-05-14 | |
| 2020-12-31 | $337,158 | 23,895 | Shares | Defined | 2021-03-08 | |
| No filing history on record for this holder in this stock. | ||||||